Last reviewed · How we verify
Sublingual ketamine wafers
At a glance
| Generic name | Sublingual ketamine wafers |
|---|---|
| Also known as | Wafermine |
| Sponsor | iX Biopharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols. (PHASE2)
- A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy (PHASE2)
- Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction (PHASE2)
- Study of Ketamine Administered Intravenously and by Sublingual Wafer
- A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual ketamine wafers CI brief — competitive landscape report
- Sublingual ketamine wafers updates RSS · CI watch RSS
- iX Biopharma Ltd. portfolio CI